CMS Proposes Major Increase in Reimbursement for Canaloplasty, page-270

IMO it comes down to costs.

Sure market share & sales are increasing BUT they have raised a large amount of $$$ to market esp. in the US & now apparently in EU so people want to know how much $$$ have been spent before buying more shares.

If they are spending $$$ to get $$$$$$ return then all will be good but hard to say ATM as maybe costs are way bigger than income so ATM spending $$$$$$ to get $$$ - the annual will tell us what the current state of play of costs vs income is, until then the market is taking a cautious approach.

If marketing/sales cost are a blow out in the annual, then the question is, will sales catchup with cost & keep growing. They have many good sales people BUT they are getting paid plenty.

HOWEVER - if you look at 'relatively old' 2023 sales/income data from the last CR preso form Feb 2024, the metrics look good BUT the sales/marketing team/push has increased dramatically since then. However, if in time the same metrics prevail & cost of production at increased scale decreases & so gross margin increases, then things will be looking very good.

The fact that EYE has no quarterly is an issue for some, including me, as you cannot keep track for cost & income so regularly.

You do your research, make your decision then time your buy, sell or hold - simple


.